Skip to main content
Edwards Lifesciences Logo

Replacement with the EVOQUE system

Replacement with the EVOQUE system

Explore the clinical evidence from TRISCEND II RCT pivotal trial:

Safety and effectiveness outcomes 1 year follow-up

Safety and effectiveness outcomes 1 year follow-up1

Download
Quality of life outcomes 1 year follow-up

Quality of life outcomes 1 year follow-up2

Download
Outcomes by baseline TR severity 18 month follow-up

Outcomes by baseline TR severity 18 month follow-up3

Download

Explore real-world outcomes with the EVOQUE system:

Safety and effectiveness outcomes in EU 30 days follow-up

Safety and effectiveness outcomes in EU 30 days follow-up4

Download

RCT, randomized controlled trial; TR, tricuspid regurgitation; TTVR, transcatheter tricuspid valve replacement;

References

  1. Hahn R.T et al. N Engl J Med. 2025;392(2):115-126 
  2. Arnold SV et al. J Am Coll Cardiol. 2024;85(3):206–216 
  3. Lurz P, et al. Eur Heart J. 2025. DOI: 10.1093/eurheartj/ehaf676
  4. Angellotti D. et al., JACC Cardiovasc Interv. 2025. Online ahead of print. doi: 10.1016/j.jcin.2025.06.002
Medical device for professional use

Medical device for professional use

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-10533 v2.0

Edwards Lifesciences Sàrl  •  Route de I’Etraz 70, 1260 Nyon, Switzerland | Edwards.com